Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study

abstract:
Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study 
June 11, 2016

---

Highlights

•

Centralized primary surgery of advanced ovarian cancer increases complete cytoreduction

•

Centralized advanced ovarian cancer care shortens time interval from surgery to chemotherapy

•

Survival improves significantly when primary care of advanced ovarian cancer is centralized

---

Objective

To evaluate centralized primary care of advanced ovarian and fallopian tube cancers in a complete population cohort in relation to complete cytoreduction, time interval from surgery to chemotherapy and relative survival.

Methods

A regional population-based cohort study of women diagnosed with primary ovarian and fallopian tube cancers and included in the Swedish Quality Registry (SQR) during 2008–2013 in a region where primary care of advanced stages was centralized in 2011. Surgical, oncological characteristics, outcomes, follow-ups and relative survivals were analyzed.

Results

There were 817 women diagnosed with ovarian and fallopian tube cancers during 2008–2013 and 523 were classified as FIGO stage III-IV and further analyzed. Primary debulking surgery (PDS) was performed in 81% and neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) in 11%. Complete cytoreduction at PDS was performed in 37% before compared to 49% after centralization (p < 0.03). The chemotherapy protocols were identical in the cohorts and they received and completed the planned chemotherapy equally. The time interval between PDS and chemotherapy was 36 days (median) before compared to 24 days after centralization (p < 0.01). The relative 3-year survival rate in women treated by PDS was 44% compared to 65% after centralization and the estimated excess mortality rate ratio (EMRR) was reduced (RR 0.58; 95% CI 0.42–0.79). Comparing the complete cohorts before and after centralization, regardless primary treatment, the relative 3-year survival rate increased from 40% to 61% with reduced EMRR (RR 0.59; 95% CI 0.45–0.76).

Conclusion

Centralized primary care of advanced ovarian and fallopian tube cancers increases complete cytoreduction, decreases time interval from PDS to chemotherapy and improves relative survival significantly.